BC Innovations | Jun 26, 2019
Distillery Therapeutics

RTN4 and S1PR2 identified as targets for stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke A team led by NovaGo Therapeutics co-founder Martin Schwab showed inhibition of RTN4 or its receptor S1PR2 could help treat stroke. In mice, levels of RTN4 and S1PR2 were elevated...
BC Innovations | Jan 11, 2017
Distillery Therapeutics

Neurology

INDICATION: Stroke Mouse studies suggest inhibiting signaling between RTN4R , RTN4RL2 and their ligands could help treat white matter stroke. In a mouse model of the disease, white matter levels of three negative regulators of Nogo...
BC Innovations | Jul 17, 2014
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Nerve damage; stroke Reticulon 4 (RTN4; NOGO-A; NOGO; NOGO-B) Rat studies suggest treatment with NOGO-A inhibitors followed by physical therapy could help improve motor recovery...
BC Innovations | Jun 30, 2011
Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Hypertension Reticulon 4 (RTN4; NOGO-A; NOGO; NOGO-B) Studies in mice and in patient samples suggest inhibiting NOGO-B could help treat pulmonary arterial hypertension (PAH)....
BC Innovations | Apr 28, 2011
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Stroke Reticulon 4 (RTN4; NOGO-A; NOGO) Studies in rats suggest that inosine plus NOGO inhibition could help increase functional motor recovery...
BioCentury | Sep 27, 2010
Emerging Company Profile

Axerion: Going beyond NOGO

While several companies are working on approaches to stimulating axonal regrowth for conditions caused or characterized by nerve damage, Axerion Therapeutics Inc. believes its NGR receptor decoys will more potently treat conditions such as acute...
BioCentury | Sep 6, 2010
Strategy

Laying siege

sanofi-aventis Group made clear in its conference call last week that it's in no hurry to complete its proposed acquisition of Genzyme Corp. - with the obvious implication that time is on its side. If so,...
BC Innovations | Jul 1, 2010
Targets & Mechanisms

Neuraminidase for spinal cord injury

Researchers at The Johns Hopkins University School of Medicine have shown that treatment with a recombinant bacterial neuraminidase can promote the recovery of motor and autonomic function in a rat model of spinal cord contusion...
BC Innovations | May 27, 2010
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Reticulon 4 (RTN4; NOGO-A; NOGO); myelin-associated glycoprotein (MAG); oligodendrocyte myelin glycoprotein (OMG; OMGP); reticulon 4 receptor (RTN4R; NGR) In vitro and...
BC Innovations | Apr 15, 2010
Targets & Mechanisms

Axon-regenerating small molecules

Researchers at the University of Miami Miller School of Medicine have identified compounds that can overcome the two main types of signals that inhibit axon growth in a damaged CNS. 1 The compounds reversed the...
Items per page:
1 - 10 of 13